Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline Gordon

Showing results (161-170 of 234) with videos related to

Pageof 24
Sort By:
The Journal of Rheumatology|December 4, 2009
Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) studySahena Haque, Caroline Gordon, David Isenberg, et al.
Frontiers in Epidemiology|March 22, 2024
Prevalence of concomitant rheumatologic diseases and autoantibody specificities among racial and ethnic groups in SLE patientsBrendan Denvir, Philip M Carlucci, Kelly Corbitt, et al.
Arthritis Research & Therapy|September 13, 2024
Prevalence of cardiovascular events in a population-based registry of patients with systemic lupus erythematosusDaniel P Joyce, Jeffrey S Berger, Allison Guttmann, et al.
Rheumatology (Oxford, England)|April 22, 2017
The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and WalesEoghan M McCarthy, Emily Sutton, Stephanie Nesbit, et al.
The Journal of Rheumatology|January 17, 2018
Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus ErythematosusSasha Bernatsky, Rosalind Ramsey-Goldman, Michelle Petri, et al.
Rheumatology (Oxford, England)|October 8, 2013
Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS)Maria J Cuadrado, Maria L Bertolaccini, Paul T Seed, et al.
Rheumatology (Oxford, England)|May 27, 2017
The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and WalesEoghan M McCarthy, Emily Sutton, Stephanie Nesbit, et al.
Rheumatology (Oxford, England)|November 1, 2022
British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: comorbidity medications used in rheumatology practiceKaren Schreiber, Margreta Frishman, Mark D Russell, et al.
Rheumatology (Oxford, England)|November 1, 2022
Executive Summary: British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: comorbidity medications used in rheumatology practiceKaren Schreiber, Margreta Frishman, Mark D Russell, et al.
Rheumatology (Oxford, England)|December 8, 2017
Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics RegisterEoghan M McCarthy, Emily Sutton, Stephanie Nesbit, et al.
Pageof 24

Showing results (161-170 of 234) with videos related to

Sort By:
Pageof 24
The Journal of Rheumatology|December 4, 2009
Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) studySahena Haque, Caroline Gordon, David Isenberg, et al.
Frontiers in Epidemiology|March 22, 2024
Prevalence of concomitant rheumatologic diseases and autoantibody specificities among racial and ethnic groups in SLE patientsBrendan Denvir, Philip M Carlucci, Kelly Corbitt, et al.
Arthritis Research & Therapy|September 13, 2024
Prevalence of cardiovascular events in a population-based registry of patients with systemic lupus erythematosusDaniel P Joyce, Jeffrey S Berger, Allison Guttmann, et al.
Rheumatology (Oxford, England)|April 22, 2017
The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and WalesEoghan M McCarthy, Emily Sutton, Stephanie Nesbit, et al.
The Journal of Rheumatology|January 17, 2018
Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus ErythematosusSasha Bernatsky, Rosalind Ramsey-Goldman, Michelle Petri, et al.
Rheumatology (Oxford, England)|October 8, 2013
Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS)Maria J Cuadrado, Maria L Bertolaccini, Paul T Seed, et al.
Rheumatology (Oxford, England)|May 27, 2017
The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and WalesEoghan M McCarthy, Emily Sutton, Stephanie Nesbit, et al.
Rheumatology (Oxford, England)|November 1, 2022
British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: comorbidity medications used in rheumatology practiceKaren Schreiber, Margreta Frishman, Mark D Russell, et al.
Rheumatology (Oxford, England)|November 1, 2022
Executive Summary: British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: comorbidity medications used in rheumatology practiceKaren Schreiber, Margreta Frishman, Mark D Russell, et al.
Rheumatology (Oxford, England)|December 8, 2017
Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics RegisterEoghan M McCarthy, Emily Sutton, Stephanie Nesbit, et al.
Pageof 24